In agreement with these findings, IHC staining revealed that metformin treatment upregulated p-AMPK and PROX1 Ser79 phosphorylation levels, and reduced Ki-67 levels in PROX1 expressing tumour tissues. Here, PRKAA2 is linked to neoplasm.